Synacthen depot

Quick links to important sections

Synacthen depot

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synacthen depot

Quick Facts

Property Description
Active ingredient Tetracosactide (also known as Cosyntropin)
Form Depot aqueous suspension for injection
Pharmacological class Adrenocorticotropic Hormone (ACTH) Analog
General purpose Stimulates the body's own cortisol and adrenal hormone production
Origin Synthetic polypeptide

What is Synacthen Depot and Its Active Ingredient?

Synacthen depot is a prescription-only medicine containing the active ingredient Tetracosactide. This substance is classified by the World Health Organization (WHO) ATC system as an Adrenocorticotropic Hormone (ACTH) Analog. Tetracosactide is a synthetic polypeptide designed to be structurally identical to the biologically active N-terminal segment (the first 24 amino acids) of the natural corticotropin hormone. Its synthetic nature is pharmacologically supported to ensure a high level of consistency and purity, which is a key factor distinguishing it from older corticotropin preparations derived from natural animal sources.

What Type of Formulation is Synacthen Depot?

Synacthen depot is specifically formulated as a depot aqueous suspension intended exclusively for intramuscular (IM) injection. The term "depot formulation" indicates that the medication is designed for a prolonged action profile, a characteristic clinically recognized as beneficial for maintaining stable systemic effects. This sustained-release function is achieved by complexing the Tetracosactide with an excipient, typically zinc phosphate, which slows the rate of absorption from the injection site. This formulation choice ensures that the medication remains active over a longer period, reducing the frequency of administration compared to rapid-acting Tetracosactide solutions.

What is the General Physiological Purpose of Tetracosactide?

The core mechanism of Tetracosactide is to function as a powerful messenger that signals directly to the adrenal cortex, the gland responsible for synthesizing hormones. The drug acts as an agonist on the adrenocorticotropic hormone receptor, compelling the adrenal glands to significantly increase their output of various endogenous hormones, principally cortisol. A typical use scenario involves its application when physician-guided support is required to restore or supplement the body’s essential hormonal systems, leveraging the body's natural capacity to produce hormones.

What side effects are possible with Synacthen depot?

Possible Side Effects and Safety Information

The safety profile of Synacthen Depot (Tetracosactide) is characterized by effects resulting from its role as an Adrenocorticotropic Hormone (ACTH) Analog, which increases the body’s production of endogenous glucocorticoid and mineralocorticoid hormones. The official regulatory documents classify adverse reactions across several System-Organ Classes.


Key Regulatory Safety Classifications

Classification Domain Documented Safety Concerns
Hormonal/Metabolic Sodium and fluid retention (leading to oedema), hypokalaemia (low potassium), hyperglycaemia, and features of Cushing's syndrome with prolonged use.
Serious Reactions Anaphylactic shock and severe systemic hypersensitivity reactions are officially classified as rare events. Other serious risks include peptic ulceration and thromboembolism.
Psychiatric/CNS Psychosis, depression, insomnia, and significant mood swings are listed as possible adverse reactions.
Musculoskeletal Long-term exposure is associated with increased risk of osteoporosis and muscle weakness (myopathy).

Exposure and Population-Specific Safety

Side effects are often contextualized by duration of exposure. Effects such as cataracts, glaucoma, and profound adrenocortical atrophy are associated with long-term use. Older adults may face a heightened risk of hypertension and osteoporosis. For pediatric patients, prolonged use carries the risk of growth retardation.

Safety-related constraints exist for use in patients with certain pre-existing conditions, including acute psychosis, active peptic ulcers, untreated systemic infections, and refractory cardiac failure, as defined in the official regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Tetracosactide (Synacthen Depot) primarily addresses two severe scenarios: acute hypersensitivity reactions and the consequences of adrenocortical overstimulation. Given the professional administration of this depot formulation, acute overdosage is generally classified as unlikely in official documentation.

Documented Manifestations and Complications

Over-exposure may lead to signs associated with exaggerated adrenocortical stimulation, which include physiological changes such as fluid retention, hypertension, hypokalaemia, and other symptoms mimicking Cushing's syndrome. Serious complications documented in regulatory sources include congestive cardiac failure, peptic ulcer with potential for perforation, and convulsions.

Population-specific overdose notes indicate that reversible cardiac hypertrophy is a documented risk associated with prolonged high-dose exposure, specifically in infants and small children.

Emergency Actions Mandated by Regulators

Official prescribing information explicitly requires patients or caregivers to seek immediate medical attention or go immediately to the nearest hospital accident and emergency department for any signs of an acute, severe reaction. This urgent action is mandated for symptoms indicative of anaphylactic shock, such as sudden onset of difficulty breathing (dyspnoea) or severe swelling (angioneurotic oedema).

Management of over-exposure is defined as symptomatic and supportive treatment, as no specific antidote is known.

Therapeutic Uses of Synacthen depot

What Synacthen Depot Treats: Main Uses and Benefits

Synacthen Depot is considered relevant in situations involving certain distressing symptoms and conditions characterized by periods of heightened symptoms. It is generally applied when short-term symptomatic assistance is needed, primarily by managing symptoms related to inflammatory or irritative states, to help patients cope more steadily with difficult episodes.

The medication is used across domains where additional symptomatic support is needed. This includes addressing acute exacerbations of multiple sclerosis (MS), specific neurological spasms in children (like infantile spasms), and severe inflammatory and rheumatic diseases.

In contexts involving acute or unstable symptom patterns, the medication provides support that helps ease the overall symptom burden, especially during flares. This short-term support helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Acute Symptom Flares

Regulatory References

  1. Synacthen Depot im® (1mg/mL) suspension for injection - NEW ZEALAND DATA SHEET

Eligibility and Restrictions for Use

Synacthen depot eligibility is defined by official regulatory documentation, establishing specific populations who must not use the medicine and those who require conditional use.

Contraindicated Populations (Must Not Use)

Individuals are absolutely contraindicated if they have known hypersensitivity to tetracosactide, ACTH, or the excipient benzyl alcohol. Contraindications also apply to patients with specific endocrine and systemic disorders, including Cushing's syndrome, primary adrenocortical insufficiency (e.g., Addison's disease), acute psychosis, active or latent peptic ulcer, and refractory heart failure. The medicine must not be used to treat asthma or other allergic conditions.

Age-Related and Conditional Eligibility

Age Restrictions: The medicine is contraindicated in premature babies and neonates (less than 1 month old) due to the benzyl alcohol content. The depot formulation is not recommended for use in infants and children between 1 month and 3 years old. Use is established for older children and adults.

Pregnancy and Lactation: Use during pregnancy is generally not recommended and is restricted to situations where the benefit clearly outweighs the potential risk. Use while breastfeeding requires caution.

Conditional Use: Special caution and monitoring are required for patients with conditions such as hypertension, osteoporosis, renal insufficiency, certain inflammatory bowel conditions, and in those receiving live virus immunisation procedures.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Synacthen depot (tetracosactide) primarily relates to its effect of stimulating the body’s release of natural glucocorticoids and mineralocorticoids, as well as its specific use in diagnostic testing.

Contraindicated and High-Risk Combinations

  • Live Virus Immunization: Administration of live virus vaccines is generally restricted during treatment due to the potential for a decreased antibody response.
  • Valproate (in pediatric patients): Concurrent use with Valproate in children should be avoided due to reports of increased risk for severe hepatotoxicity (jaundice).

Interactions Requiring Dosage Adjustment

Synacthen depot may necessitate adjustments to the dose of other medications due to the stimulated release of endogenous corticosteroids:

  • Antidiabetic Drugs: The dosage may need to be readjusted as the corticosteroid effect can lead to increased blood glucose levels.
  • Antihypertensive Drugs: The dosage may require readjustment due to the mineralocorticoid effects, which can cause sodium and water retention.

Interference with Diagnostic Testing

Several substances can interfere with the accuracy of the plasma cortisol measurement when Synacthen depot is used for diagnostic purposes, requiring specific timing adjustments or discontinuation prior to the test:

  • Glucocorticoids (e.g., Hydrocortisone, Cortisone): Pre-test doses must be omitted to prevent interference.
  • Estrogen-Containing Drugs: May need to be discontinued several weeks prior to testing as they can artificially elevate total plasma cortisol levels by increasing binding globulin.

Use With Caution

Use with caution is advised when co-administering with other anticonvulsant medications (e.g., phenytoin, phenobarbital, primidone) due to documented concerns regarding an increased risk of liver damage.

Mechanism of Action

How Synacthen depot Works: Pharmacodynamic Mechanism

Synacthen depot, containing tetracosactide, acts as an agonist for the melanocortin 2 receptor (MC2R) on the cell membranes of the adrenal cortex. Following controlled, sustained release from the depot formulation, tetracosactide binds MC2R, initiating an intracellular signaling cascade. This activation primarily modulates the cyclic adenosine monophosphate (cAMP) second messenger system within adrenocortical cells. The resulting increase in intracellular cAMP level stimulates the synthesis and secretion of endogenous cortisol (a glucocorticoid), mineralocorticoids, and, to a lesser extent, androgens. The sustained elevation of circulating cortisol levels then mediates a wide spectrum of anti-inflammatory and immunomodulatory physiological effects through the glucocorticoid receptor (GR) in target tissues throughout the body.

Dosage and Administration Information

Synacthen depot is an injectable medicine containing Tetracosactide, which is administered according to specific principles defined in official documentation. The approved method of delivery for this long-acting formulation is strictly a deep intramuscular (IM) injection. It is essential that the aqueous suspension be shaken thoroughly immediately before use to ensure the uniform distribution of the depot complex. The medicine is not intended for intravenous administration.

Official Dosing Regimens

The official dosing pattern begins with a period of daily administration for initial or acute situations, typically a dose of 1 mg once per day. Following this phase, the schedule transitions to an intermittent regimen for continued management, often involving 1 mg administered every two or three days.

Dosing for pediatric patients is generally lower, with specific starting doses of 0.25 mg to 0.5 mg daily established for infants, such as those being treated for infantile spasms.

Course Duration and Tapering

The overall use of this medicine is designed for a short-term course to control acute symptoms. When the course of treatment concludes, the frequency and dose must be gradually reduced (tapered) to align with official protocol. This prescribed reduction is a core procedural component of discontinuing the medication, as specified in official labeling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Synacthen Depot


1. Evidence for Use in Infantile Spasms (West's Syndrome)

Research examining Synacthen depot (Tetracosactide) for infantile spasms has primarily involved Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize the results of multiple studies. This approach is used in research exploring how symptoms change over time, where the outcomes of the studied treatment were evaluated in the same research setting as other standard therapies for this condition. The study populations were mainly infants with newly diagnosed spasms.

The outcomes related to physical discomfort that researchers studied included measured changes in the frequency of clinical spasms and the patterns of abnormal electrical activity in the brain (known as hypsarrhythmia), which is measured by EEG. Studies report how symptoms evolved in the observed populations, and findings describe patterns related to the time to change in spasm frequency in the studied populations. Research highlights changes measured during the study period, indicating that some trials reported patterns related to the time required for a measured response in the studied groups.

2. Evidence for Use in Acute Multiple Sclerosis Exacerbations

Research exploring Synacthen depot’s role in acute exacerbations, or flare-ups, of multiple sclerosis (MS) largely stems from historical controlled clinical trials and subsequent analyses. This research explored short-term symptom changes in adult patients experiencing acute or disruptive episodes. Studies monitored outcomes describing episodic or acute changes, focusing on the measured time interval until symptom change from the flare and measurements of neurological function using standardized scales.

Findings describe patterns observed in the studies, describing a pattern where the time required for symptom change, as measured in the immediate post-treatment period, was noted in the studies. Studies report how symptoms evolved in the observed populations, indicating that the change on disability scales was a measured event within the short time frame of the trials.

3. What is Still Uncertain About Synacthen Depot Research

This section summarizes the main evidence gaps in the research for this medicine. The main evidence gaps concern the lack of current, large-scale comparative trials for MS and inflammatory diseases that match the rigor and scope of modern drug development. Findings were mixed or limited for certain outcomes, particularly those related to long-term effects, relapse prevention, and disease modification across all indications. The data for certain groups remain insufficient, and research is ongoing to continuously evaluate and contextualize the existing evidence landscape.

Key Studies & References Synacthen Depot im® (1mg/mL) suspension for injection - NEW ZEALAND DATA SHEET

Frequently Asked Questions (FAQ)

Common questions about Synacthen depot (FAQ)

Q: Is Synacthen depot the same as Synacthen or are they different?

A: Synacthen depot contains the same active ingredient, tetracosactide, as the standard Synacthen injection. The key difference lies in the formulation: the 'depot' version is designed for a prolonged, slow-release action. This allows the medication to remain active for longer, which reduces the frequency of administration compared to the standard solution.

Q: Does Synacthen depot work like a steroid, even though it's a hormone?

A: According to official product information, Synacthen depot works by stimulating the adrenal glands to produce more of the body’s own natural hormones, primarily cortisol. Cortisol is a glucocorticoid, a type of steroid hormone, which then mediates anti-inflammatory and immunomodulatory effects in the body.

Q: How quickly should I expect to see an effect after a Synacthen depot injection?

A: The time required for a noticeable change in symptoms is monitored by a medical professional and can be specific to the individual patient and the condition being managed. Since this is a depot formulation, it is designed for a sustained, slow-release effect rather than an immediate response.

Q: How long do the effects of a single Synacthen depot injection last?

A: The depot formulation is designed for prolonged action. This sustained release profile allows the medication to be administered on an intermittent schedule, such as every two or three days, which is often used for the continued management of certain conditions.

Q: Is weight gain a common side effect of Synacthen depot treatment?

A: Weight gain is listed in regulatory documents as a possible adverse reaction. Prolonged use of the medication can lead to features similar to Cushing's syndrome, which often involves weight gain, particularly around the face and trunk, along with high blood pressure.

Q: Can Synacthen depot affect blood sugar levels?

A: Official information confirms that Synacthen depot can cause an increase in blood sugar levels, a condition known as hyperglycaemia. Official documentation states that if a patient is taking antidiabetic drugs, a medical professional may need to review or adjust the patient's dosage due to this effect.

Q: Are there any foods or drinks to avoid while on Synacthen depot?

A: Due to the medicine's potential to cause sodium and water retention in the body, a low-salt diet may be advisable. It is important for patients to consult with their healthcare provider regarding any necessary dietary changes or restrictions.

Q: Can Synacthen depot interact with birth control pills?

A: The official documentation mentions that estrogen-containing drugs, which are found in many oral contraceptives, may interfere with the accuracy of diagnostic cortisol tests. Healthcare professionals advise that patients disclose all hormone-containing medicines currently being taken, as they may interfere with diagnostic tests.

Q: What happens to the body's own cortisol production when using Synacthen depot?

A: Synacthen depot works by stimulating the adrenal glands to significantly increase their own output of natural cortisol. However, prolonged use of the medication is associated with a risk of adrenocortical atrophy, which is a decrease in the size and function of the adrenal cortex.

Q: Are headaches a common side effect of Synacthen depot?

A: Headache is listed in regulatory product information as a possible neurological adverse reaction associated with this medicine.

Q: Can Synacthen depot be used during pregnancy or while breastfeeding?

A: Use during pregnancy is generally not recommended and is restricted to situations where the potential benefit clearly outweighs the potential risks. Use while breastfeeding requires careful medical assessment and caution.

Q: Does Synacthen depot affect fertility or hormones besides cortisol?

A: The medication stimulates the release of mineralocorticoids and, to a lesser extent, androgens (sex hormones). Side effects can include menstrual problems. However, specific effects on long-term fertility are not explicitly detailed in the general safety information.

Q: Can Synacthen depot cause skin changes, like thinning or bruising?

A: Yes, regulatory documents list possible skin disorders as adverse reactions. These may include thinning of the skin, easy bruising, the appearance of red or purple spots, and acne.

Q: Is it normal to feel a temporary 'high' or rush after the injection?

A: Possible psychiatric adverse reactions listed in the official product information include mood changes, insomnia, and depression. Any significant or unusual mood changes or feelings of 'rush' experienced after receiving the injection should be reported to a healthcare provider.

Q: What is the typical age range for patients prescribed Synacthen depot for non-rheumatic conditions?

A: Use is generally established for adults and older children, typically those aged 3 years and older. The medicine is specifically contraindicated for use in premature babies and neonates.

Q: What conditions is Synacthen depot most commonly prescribed for?

A: Official indications for this medicine include certain types of seizures in children (such as infantile spasms), acute exacerbations (flare-ups) of multiple sclerosis, and as a short-term treatment for some rheumatic diseases when corticosteroids are usually indicated.

Q: What makes Synacthen depot different from other ACTH medications?

A: Synacthen depot contains tetracosactide, which is a synthetic form of the active part of the natural ACTH hormone. This synthetic nature is often highlighted as distinct from older corticotropin preparations derived from animal sources, ensuring a high level of consistency and purity.

Q: Is Synacthen depot ever prescribed for muscle or joint pain?

A: Official indications include its use as short-term therapy for certain rheumatic diseases, which often involve joint pain or inflammation, in situations where corticosteroid therapy is typically recommended.

Q: Is it safe to take over-the-counter pain relievers while using Synacthen depot?

A: Co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen is not specifically listed as an interaction, but using them with medicines that increase the body’s corticosteroids can increase the risk of serious gastrointestinal side effects, such as ulcers. Consultation with a healthcare provider is necessary before taking any over-the-counter pain relievers.

Q: Can older adults use Synacthen depot safely?

A: Older adults may use this medicine, but regulatory safety sections indicate they may face a heightened risk of certain side effects, including high blood pressure (hypertension) and osteoporosis. Therefore, use requires special caution and consistent medical monitoring.

Q: What are the most commonly reported side effects of Synacthen depot?

A: Regulatory documents list numerous possible adverse reactions, including fluid retention, changes in mood, and high blood sugar. Although frequencies are not always provided, known serious but rare risks include anaphylactic shock and peptic ulceration.

Q: Can Synacthen depot cause changes in mood or behavior?

A: Yes, the official product information lists possible psychiatric adverse reactions. These can include psychosis, depression, insomnia, and significant mood swings.

Q: Is fatigue a normal side effect when starting Synacthen depot?

A: Fatigue is listed in official regulatory safety guidelines as a possible neurological side effect associated with the use of this type of medication.

Q: Does Synacthen depot suppress the immune system?

A: The medicine mediates anti-inflammatory and immunomodulatory effects by increasing cortisol. Due to its impact on the body's defenses, patients are warned about an increased susceptibility to infection, and live virus vaccines are generally restricted during treatment.

Q: Can Synacthen depot cause problems with sleep?

A: Yes, insomnia, which is trouble falling or staying asleep, is listed in the psychiatric/CNS classification as a possible adverse reaction.

Q: Is there a risk of bone density loss with Synacthen depot use?

A: Yes, long-term exposure to the effects of this medicine is associated with an increased risk of developing osteoporosis, which is the thinning of the bones, and muscle weakness.

Q: Are there any restrictions on driving or operating machinery while taking Synacthen depot?

A: Regulatory information advises that if a patient experiences side effects such as dizziness, headache, or blurred vision after receiving the injection, they should not drive or operate heavy machinery until those effects have completely worn off.

Q: What should be done if a scheduled Synacthen depot injection is missed?

A: Since this medicine is administered by a healthcare professional, a missed dose is unlikely in a monitored setting. If a patient has concerns about a missed or delayed injection, they should contact their healthcare provider for guidance.

Q: Can Synacthen depot be used by people with a history of stomach ulcers?

A: The medicine is strictly contraindicated (must not be used) in patients with an active or latent peptic ulcer. It is advised to use the medication with caution and close monitoring in patients who have a past history of stomach or bowel problems.

Q: Is Synacthen depot a branded name, and if so, what is the generic name?

A: Synacthen depot is a branded trade name for the product. The active pharmaceutical ingredient is tetracosactide, which is the generic name for the substance (also sometimes referred to as tetracosactrin or cosyntropin).

Q: Is it possible to develop a tolerance to Synacthen depot over time?

A: Regulatory safety information indicates that patients receiving repeated injections of tetracosactide may develop Anti-ACTH antibodies. The presence of these antibodies can potentially mediate adverse reactions.

Q: What are the signs of an allergic reaction to Synacthen depot?

A: Signs of a severe systemic hypersensitivity reaction can include itching, flushing, dizziness, nausea, vomiting, swelling of the face, lips, or tongue, and difficulty breathing. Anaphylactic shock is rare but is classified as a serious risk.

Q: Is there a maximum duration for Synacthen depot treatment?

A: The medicine is generally intended for a short-term course to control acute symptoms. Official documentation warns that long-term use is associated with a greater risk of severe side effects, such as glaucoma, cataracts, and adrenocortical atrophy.

Q: Why is Synacthen depot sometimes used for conditions that don't seem hormonal?

A: The drug's primary action is hormonal (stimulating cortisol production), but the reason for its use in non-hormonal conditions, such as multiple sclerosis or spasms, is because the resulting cortisol mediates powerful anti-inflammatory and immune-modifying effects throughout the body.

How should Synacthen depot be stored and disposed of?

Storage and Disposal of Synacthen Depot

Synacthen Depot (Tetracosactide acetate) must be stored under specific environmental constraints to maintain product stability, as required by official labeling.

Storage Requirements

Condition Requirement
Temperature Store in a refrigerator between 2 C and 8 C.
Protection Keep in the original outer carton and protected from light.
Handling The ampoule must be shaken before use.
Child Safety Must be kept out of the sight and reach of children.
Stability Any unused contents remaining after opening must be discarded immediately.

Disposal

Any unused medicine or waste material must be disposed of in accordance with local regulations. Medicines should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Synacthen depot found in:

A-Z Index: